Pathophysiologic distinctions between sensitive skin syndrome and rosacea: Evidence from a sensitive versus non-sensitive skin pilot study - 22/05/26
Doi : 10.1016/j.jaad.2026.04.1986
Nikita Menta, BA a, Savanna I. Vidal, BS a, Nadège Lachmann, MS b, Giovanni Pellacani, MD, PhD c, Adam Friedman, MD a, ⁎ 
a Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia
b Galderma Sensitive Skincare Faculty, Lausanne, Switzerland
c Department of Hematology, Oncology and Dermatology, La Sapienza University, Rome, Italy
∗ Correspondence to: Adam Friedman, MD, Department of Dermatology, George Washington University School of Medicine and Health Sciences, 2150 Pennsylvania Ave NW Fl. 2 South, Washington, DC 20037 Department of Dermatology George Washington University School of Medicine and Health Sciences 2150 Pennsylvania Ave NW Fl. 2 South Washington DC 20037
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 22 May 2026
Key words : burning, cathelicidin, demodex, dermcidin, erythema, rosacea, sensitive skin syndrome, stinging
| Funding sources: Menta's work was funded through independent research grants from Incyte and Johnson & Johnson . Vidal's work was funded through an independent research grant from Galderma . |
|
| Patient consent: All participants provided written informed consent to participate in this study. |
|
| IRB approval status: Reviewed and approved by Comité De Protection Des Personnes, Ouest 5, Rennes; number 2019-A00374-53. |
© 2026
The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?